Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors

NCT02454062 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT02454062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02454062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2013
Completion date
September 30, 2017
Enrollment
120 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors